Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 149

Sort by

Sort Order Select

Journal Articles

In-class transition from bortezomib to ixazomib-based regimens in transplant-ineligible patients with newly diagnosed multiple myeloma: A retrospective, observational, real-world study conducted in China

Jieqiong Zhou, Gang An, Yuntong Liu, Wenqiang Yan, Chenxing Du, Shuhui Deng, Weiwei Sui, Yan Xu, Lugui Qiu

Blood (2025) 146 (Supplement 1): 7550.

https://doi.org/10.1182/blood-2025-7550

Published: 2025

Journal Articles

Combining axicabtagene ciloleucel (axi-cel) or relmacabtagene autoleucel (relma-cel) with HDT/ASCT in relapsed/refractory large B-cell lymphoma: A single-center experience

Wei LIU, Yan Xu, Yi Wang, Weiwei Sui, Wenyang Huang, Lugui Qiu, Dehui Zou

Blood (2025) 146 (Supplement 1): 3720.

https://doi.org/10.1182/blood-2025-3720

Published: 2025

Journal Articles

BCMA CAR T-cell therapy in newly diagnosed transplant-ineligible multiple myeloma: An open label, single-arm, phase 2 study (CAREMM-001)

Wenqiang Yan, Chenxing Du, Hesong Zou, Shuaishuai Zhang, Shuhui Deng, Yan Xu, Shuhua Yi, Dehui Zou, Lugui Qiu, Gang An

Blood (2025) 146 (Supplement 1): 2293.

https://doi.org/10.1182/blood-2025-2293

Published: 2025

Journal Articles

Isatuximab (Isa) subcutaneous (SC) via an on-body injector (OBI) vs isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): East asia subgroup results from the randomized, non-inferiority, phase 3 iraklia study

Blood (2025) 146 (Supplement 1): 5819.

https://doi.org/10.1182/blood-2025-5819

Published: 2025

Journal Articles

Treatment outcomes in patients with newly diagnosed multiple myeloma receiving ixazomib as initial therapy: A retrospective, observational, real-world historical database analysis from China

Gang An, Jieqiong Zhou, Yuntong Liu, Wenqiang Yan, Chenxing Du, Shuhui Deng, Weiwei Sui, Yan Xu, Lugui Qiu

Blood (2025) 146 (Supplement 1): 2246.

https://doi.org/10.1182/blood-2025-2246

Published: 2025

Journal Articles

Genomic assessment of acquired mutations in participants with CLL/SLL treated with nemtabrutinib in the Phase 2 bellwave-003 study

Blood (2025) 146 (Supplement 1): 797.

https://doi.org/10.1182/blood-2025-797

Published: 2025

Journal Articles

Pola-R-edch shows high response rates in high-risk aggressive B-cell lymphomas or PMBCL: A phase 2 study

Wei LIU, Yi Wang, Huimin Liu, Qi Wang, Hesong Zou, Yan Xu, Wenyang Huang, Lugui Qiu, Dehui Zou

Blood (2025) 146 (Supplement 1): 3683.

https://doi.org/10.1182/blood-2025-3683

Published: 2025

Journal Articles

Single-cell transcriptomics reveals pathogenic interactions between clonal plasma cells and monocytes in POEMS syndrome

Xinli Han, Chi Li, Luyao Shi, Tingting Lei, Xiaotong Zhang, Zongyang Li, Kairan Li, Saisai Sun, Yan Xu, Lu Yang, Chong Wang, Bian Zhilei, Shujuan Wang

Blood (2025) 146 (Supplement 1): 3929.

https://doi.org/10.1182/blood-2025-3929

Published: 2025

Journal Articles

Metabolomics profiling and machine learning prediction of efficacy and prolonged cytopenia in patients with large B-cell lymphoma undergoing CAR-T therapy

Hesong Zou, Chen Jia, Wei LIU, Huimin Liu, Yi Wang, Yan Xu, Shuhua Yi, Gang An, Lugui Qiu, Dehui Zou

Blood (2025) 146 (Supplement 1): 1938.

https://doi.org/10.1182/blood-2025-1938

Published: 2025

Journal Articles

Phase 2 bellwave-003 cohort f: Updated clinical outcomes of nemtabrutinib in participants with relapsed or refractory marginal zone lymphoma

Alessandra Tucci, Yair Herishanu, Juan Dupont, Sarit Assouline, Lori Leslie, Thor Hoyer, Pier Luigi Zinzani, Yan Xu, Mohammed Z.H. Farooqui, Jing Yang, Muhit Ozcan

Blood (2025) 146 (Supplement 1): 1801.

https://doi.org/10.1182/blood-2025-1801

Published: 2025

Journal Articles

A prospective, single-center, single-arm clinical trial of zanubrutinib monotherapy and zfcg combined therapy was given sequentially for the treatment of primary symptomatic CLL/SLL (Stop Trial)

Tingyu Wang, Yuting Yan, Ying Yu, Xiong Wenjie, Rui Lv, Tengteng Yu, Wei LIU, Yan Xu, Weiwei Sui, Wenyang Huang, Shuaishuai Zhang, Qi Wang, Lugui Qiu, Shuhua Yi

Blood (2025) 146 (Supplement 1): 2124.

https://doi.org/10.1182/blood-2025-2124

Published: 2025

Journal Articles

Equecabtagene autoleucel in patients with relapsed or refractory multiple myeloma: The first real-world data from a single Chinese center

Blood (2025) 146 (Supplement 1): 4074.

https://doi.org/10.1182/blood-2025-4074

Published: 2025

Journal Articles

Updated results of a first-in-human, Phase Ⅰa/Ⅰb study of QLS32015 (GPRC5D×CD3) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

Gang An, Baijun Fang, Xiaobing Huang, Yan Xu, Fei Li, Zhen Cai, Xiaojing Yan, Xianqi Feng, Wuping Li, Xiangmin Tong, Zengjun Li, Yuzhang Liu, Feifei Che, Xin'ai Yang, Xianlin Duan, Peng Shao, Xiaoyan Kang, Lugui Qiu

Blood (2025) 146 (Supplement 1): 4049.

https://doi.org/10.1182/blood-2025-4049

Published: 2025

Journal Articles

Circulating tumor plasma cells as an independent prognostic marker in newly diagnosed multiple myeloma: Clinical correlation and immunophenotypic insights

Yating Li, Yuntong Liu, Jieqiong Zhou, Wenqiang Yan, Jian Cui, Jingyu Xu, Chenxing Du, Shuhui Deng, Yan Xu, Lugui Qiu, Gang An

Blood (2025) 146 (Supplement 1): 5761.

https://doi.org/10.1182/blood-2025-5761

Published: 2025

Journal Articles

Preliminary analysis of orelabrutinib combined with obinutuzumab in the treatment of marginal zone lymphoma (Orion Study)

Rui Lv, Tingyu Wang, Yuting Yan, Tengteng Yu, Xiong Wenjie, Ying Yu, Qi Wang, Shuaishuai Zhang, Hesong Zou, Shuhui Deng, Yan Xu, Dehui Zou, Liang Huang, Gang An, Lugui Qiu, Shuhua Yi

Blood (2025) 146 (Supplement 1): 5379.

https://doi.org/10.1182/blood-2025-5379

Published: 2025

Journal Articles

Impact of race on the incidence, diagnosis and outcomes of pregnancy-associated venous thromboembolism: A nested case-control study

Yan Xu, Michael Pugliese, Leslie Skeith, Manish Sood, A. Kinga Malinowski, Steven Hawken, Isabelle Malhamé, Jude Mary Cénat, Tzu-Fei Wang, Jerome Federspiel, Marc Carrier

Blood (2025) 146 (Supplement 1): 1340.

https://doi.org/10.1182/blood-2025-1340

Published: 2025

Journal Articles

Nemtabrutinib in participants with relapsed or refractory follicular lymphoma: Updated efficacy and safety from cohort g of the phase 2 bellwave-003 study

Wojciech Jurczak, Ana Basquiera, Isabelle Fleury, Sujun Gao, Arpad Illes, Andras Masszi, Antonio Pinto, Sanne Lugthart, Omur Sevindik, Iryna Kriachok, Elizabeth Phillips, Fei Li, Chan Cheah, Yan Xu, Mohammed Z.H. Farooqui, Jing Yang, Fangfang Lv

Blood (2025) 146 (Supplement 1): 3570.

https://doi.org/10.1182/blood-2025-3570

Published: 2025

Journal Articles

Ixazomib combined with daratumumab-based regimens as first-line therapy for transplant-ineligible patients with newly diagnosed multiple myeloma: A real-world historical database analysis from China

Jieqiong Zhou, Gang An, Yuntong Liu, Wenqiang Yan, Chenxing Du, Shuhui Deng, Weiwei Sui, Yan Xu, Lugui Qiu

Blood (2025) 146 (Supplement 1): 8142.

https://doi.org/10.1182/blood-2025-8142

Published: 2025

Journal Articles

Promising safety and efficacy of equecabtagene autoleucel (eque-cel) followed ASCT in ultra high-risk multiple Myeloma (UHR-MM) patients: primary real world data from a single center

Blood (2025) 146 (Supplement 1): 2299.

https://doi.org/10.1182/blood-2025-2299

Published: 2025

Journal Articles

Serum free light chain escape before IMWG progression: A predictive marker and a therapeutic opportunity

Blood (2025) 146 (Supplement 1): 4015.

https://doi.org/10.1182/blood-2025-4015

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

In-class transition from bortezomib to ixazomib-based regimens in transplant-ineligible patients with newly diagnosed multiple myeloma: A retrospective, observational, real-world study conducted in China

Combining axicabtagene ciloleucel (axi-cel) or relmacabtagene autoleucel (relma-cel) with HDT/ASCT in relapsed/refractory large B-cell lymphoma: A single-center experience

BCMA CAR T-cell therapy in newly diagnosed transplant-ineligible multiple myeloma: An open label, single-arm, phase 2 study (CAREMM-001)

Isatuximab (Isa) subcutaneous (SC) via an on-body injector (OBI) vs isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): East asia subgroup results from the randomized, non-inferiority, phase 3 iraklia study

Treatment outcomes in patients with newly diagnosed multiple myeloma receiving ixazomib as initial therapy: A retrospective, observational, real-world historical database analysis from China

Genomic assessment of acquired mutations in participants with CLL/SLL treated with nemtabrutinib in the Phase 2 bellwave-003 study

Pola-R-edch shows high response rates in high-risk aggressive B-cell lymphomas or PMBCL: A phase 2 study

Single-cell transcriptomics reveals pathogenic interactions between clonal plasma cells and monocytes in POEMS syndrome

Metabolomics profiling and machine learning prediction of efficacy and prolonged cytopenia in patients with large B-cell lymphoma undergoing CAR-T therapy

Phase 2 bellwave-003 cohort f: Updated clinical outcomes of nemtabrutinib in participants with relapsed or refractory marginal zone lymphoma

A prospective, single-center, single-arm clinical trial of zanubrutinib monotherapy and zfcg combined therapy was given sequentially for the treatment of primary symptomatic CLL/SLL (Stop Trial)

Equecabtagene autoleucel in patients with relapsed or refractory multiple myeloma: The first real-world data from a single Chinese center

Updated results of a first-in-human, Phase Ⅰa/Ⅰb study of QLS32015 (GPRC5D×CD3) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

Circulating tumor plasma cells as an independent prognostic marker in newly diagnosed multiple myeloma: Clinical correlation and immunophenotypic insights

Preliminary analysis of orelabrutinib combined with obinutuzumab in the treatment of marginal zone lymphoma (Orion Study)

Impact of race on the incidence, diagnosis and outcomes of pregnancy-associated venous thromboembolism: A nested case-control study

Nemtabrutinib in participants with relapsed or refractory follicular lymphoma: Updated efficacy and safety from cohort g of the phase 2 bellwave-003 study

Ixazomib combined with daratumumab-based regimens as first-line therapy for transplant-ineligible patients with newly diagnosed multiple myeloma: A real-world historical database analysis from China

Promising safety and efficacy of equecabtagene autoleucel (eque-cel) followed ASCT in ultra high-risk multiple Myeloma (UHR-MM) patients: primary real world data from a single center

Serum free light chain escape before IMWG progression: A predictive marker and a therapeutic opportunity

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only